29 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
12 Jul 23
Report of Foreign Private Issuer
12:00am
that the company complies with the requirements as to director independence and audit committee and compensation committee composition applicable to companies
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
Independence
Our board of directors consists of nine members. The directors will serve until our next annual meeting and until their successors are duly … the general test for independence of board and committee members.
Our board of directors adopted an audit committee charter effective upon the listing
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
10 Nov 22
Current Report
5:28pm
other directors (i) meets the independence requirements under the Exchange Act, (ii) meets the independence requirements of Nasdaq rules for membership
424B5
SCNI
Scinai Immunotherapeutics Ltd
28 Dec 21
Prospectus supplement for primary offering
5:20pm
to, among other things, board independence requirements, director nomination procedures and quorum requirements. In addition, we may follow our home country
424B5
usyfzct5z4yp0
27 Dec 21
Prospectus supplement for primary offering
6:22am
424B5
cvsl2vap3v9nag
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
6ipbb1kmz0g9a 1e9
29 Jan 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
u8hbn5
2 Oct 20
Condensed Interim Financial Statements
12:00am
424B5
d4na 99cpovm
2 Oct 20
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
vn72a
25 Feb 20
Report of Foreign Private Issuer
12:41pm
6-K
EX-99.1
m1oy0 jgjw01r1l44voo
13 Jan 20
Report of Foreign Private Issuer
6:24am
POS AM
rbm9q4ayosfknlr
7 Jan 20
Prospectus update (post-effective amendment)
10:51am
F-1/A
7h4vo yivs501lj2
7 Jun 19
Registration statement (foreign) (amended)
11:42am
F-1/A
oyv4 yaz8
6 Jun 19
Registration statement (foreign) (amended)
12:00am
F-1/A
ns7j2ujjkuwlenn
30 May 19
Registration statement (foreign) (amended)
8:46am